Search - tctmd.com

Displaying 801 - 820 of 952

Sort: Relevancy | Date

News Conference News

Drug-Eluting Balloons an Option for Patients with BMS Restenosis, High Bleeding Risk

November 17, 2011

News Conference News

Supervised Exercise Improves Walking Outcomes Better Than Stenting in PAD

November 16, 2011

News Conference News

Higher Dosing Improves Clopidogrel Response in Carriers of Variant Genes

November 16, 2011

News Conference News

MI FREEE: Free Post-MI Drugs Reduce Events, Costs

November 15, 2011

News Conference News

PRISM Individualized Informed Consent Improves PCI Choice, Experience

November 14, 2011

News Industry News

REMEDEE Study Meets Primary Endpoint: OrbusNeich’s Combo™ Dual Therapy Stent Is Non-Inferior to DES

November 13, 2011

News Conference News

AIDA STEMI: No Advantage for Intracoronary vs. Intravenous Abciximab

November 13, 2011

News Industry News

Paclitaxel-coated balloon angioplasty demonstrates superior results

November 10, 2011

News Conference News

EVOLVE: Bioabsorbable EES Noninferior to Permanent Polymer Version

November 10, 2011

News Industry News

Clinical trial establishes non-inferiority of drug-eluting stent with a bioabsorbable polymer

November 10, 2011

News Conference News

RAPID GENE: Validation of Point-of-Care Genetic Testing

November 09, 2011

News Conference News

PARIS: Early DAPT Nonadherence, A Small Problem with Big Consequences

November 09, 2011

News Industry News

Low CV Event Rate Prompts Closure of Prasugrel Trial

November 09, 2011

News Industry News

Tailored therapy for anti-platelet drugs using a novel point-of-care genetic test provides improved response to medications compared to current standard of care

November 08, 2011

News Industry News

Risk of late stent thrombosis continues for up to seven years in patients with first generation drug-eluting stents; risk factors identified

November 08, 2011

News Industry News

Patients with ACS and/or diabetes who show poor response to dual antiplatelet therapy

November 08, 2011

News Industry News

OrbusNeich’s Genous Stent Demonstrates Most Rapid Coronary Vessel Healing Compared to Bare Metal and Drug Eluting Stents at 14 Days Post-Implantation

November 08, 2011

News Industry News

Non-adherence to dual antiplatelet therapy following percutaneous coronary intervention results in higher rates of ischemic and bleeding events

November 08, 2011

News Conference News

Mock Jury Votes on DAPT Duration: 12 Months Remains Best Option for Most Patients

November 08, 2011

News Conference News

Low Event Rates with EES Sustained at 2 Years

November 08, 2011

Advertisement

Drug-Eluting Balloons an Option for Patients with BMS Restenosis, High Bleeding Risk

Supervised Exercise Improves Walking Outcomes Better Than Stenting in PAD

Higher Dosing Improves Clopidogrel Response in Carriers of Variant Genes

MI FREEE: Free Post-MI Drugs Reduce Events, Costs

PRISM Individualized Informed Consent Improves PCI Choice, Experience

REMEDEE Study Meets Primary Endpoint: OrbusNeich’s Combo™ Dual Therapy Stent Is Non-Inferior to DES

AIDA STEMI: No Advantage for Intracoronary vs. Intravenous Abciximab

Paclitaxel-coated balloon angioplasty demonstrates superior results

EVOLVE: Bioabsorbable EES Noninferior to Permanent Polymer Version

Clinical trial establishes non-inferiority of drug-eluting stent with a bioabsorbable polymer

RAPID GENE: Validation of Point-of-Care Genetic Testing

PARIS: Early DAPT Nonadherence, A Small Problem with Big Consequences

Low CV Event Rate Prompts Closure of Prasugrel Trial

Tailored therapy for anti-platelet drugs using a novel point-of-care genetic test provides improved response to medications compared to current standard of care

Risk of late stent thrombosis continues for up to seven years in patients with first generation drug-eluting stents; risk factors identified

Patients with ACS and/or diabetes who show poor response to dual antiplatelet therapy

OrbusNeich’s Genous Stent Demonstrates Most Rapid Coronary Vessel Healing Compared to Bare Metal and Drug Eluting Stents at 14 Days Post-Implantation

Non-adherence to dual antiplatelet therapy following percutaneous coronary intervention results in higher rates of ischemic and bleeding events

Mock Jury Votes on DAPT Duration: 12 Months Remains Best Option for Most Patients

Low Event Rates with EES Sustained at 2 Years

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content